Outlook Therapeutics Inc (OTLK)

[conix]

Outlook to re-submit application for eye disorder drug in Sept. after FDA correspondence


Jun. 14, 2022 8:45 AM ET
Outlook Therapeutics, Inc. (OTLK)

By: Anuron Mitra, SA News Editor

AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background

Outlook Therapeutics (NASDAQ:OTLK) on Tuesday reiterated that it expects to re-submit its biologics license application (BLA) in Sept. for its ONS-5010 formulation for the treatment of wet age-related macular degeneration, a retinal disease.

The company reiterated the expectations for Sept. following the receipt of additional correspondence from the U.S. FDA.

OTLK stock had slumped on May 31 after the company voluntarily withdrew the BLA after the FDA's request for additional information.